News
PLRX
14.37
-0.83%
-0.12
Weekly Report: what happened at PLRX last week (1028-1101)?
Weekly Report · 1d ago
Weekly Report: what happened at PLRX last week (1021-1025)?
Weekly Report · 10/28 09:03
Weekly Report: what happened at PLRX last week (1014-1018)?
Weekly Report · 10/21 09:03
Pliant Therapeutics highlights INTEGRIS-PSC Phase 2a data on bexotegrast
TipRanks · 10/17 12:10
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast In Primary Sclerosing Cholangitis To Be Highlighted In A Late-Breaking Presentation At The Liver Meeting 2024
Benzinga · 10/17 12:01
Weekly Report: what happened at PLRX last week (1007-1011)?
Weekly Report · 10/14 09:03
Weekly Report: what happened at PLRX last week (0930-1004)?
Weekly Report · 10/07 09:03
PLIANT THERAPEUTICS APPOINTS GARY PALMER, M.D. AS SENIOR VICE PRESIDENT OF MEDICAL AFFAIRS
Reuters · 10/01 20:35
Press Release: Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Dow Jones · 10/01 20:35
PLIANT THERAPEUTICS INC - GRANTS 120,000 STOCK OPTIONS TO NEW SVP GARY PALMER
Reuters · 09/30 20:45
Weekly Report: what happened at PLRX last week (0923-0927)?
Weekly Report · 09/30 09:03
Weekly Report: what happened at PLRX last week (0916-0920)?
Weekly Report · 09/23 09:03
Pliant Therapeutics (PLRX) Gets a Buy from Piper Sandler
TipRanks · 09/17 10:57
Weekly Report: what happened at PLRX last week (0909-0913)?
Weekly Report · 09/16 09:03
Bullish on Bexo: Pliant Therapeutics’ Promising IPF Treatment Backed by Strong Clinical Evidence
TipRanks · 09/16 06:16
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 09/13 11:08
HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Benzinga · 09/13 10:58
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential
TipRanks · 09/13 10:26
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Simply Wall St · 09/13 10:20
Pliant Therapeutics: Good Data, But Will Need Watching
Seeking Alpha · 09/11 22:08
More
Webull provides a variety of real-time PLRX stock news. You can receive the latest news about Pliant Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PLRX
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.